复发/难治弥漫性大B淋巴瘤免疫治疗进展  

Progress in Immunotherapy for Relapsed or Refractory Diffuse Large B Lymphoma

作　　者：万梦迪 洪煌明 Wan Mengdi;Hong Huangming(Department of Medical Oncology,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,Sichuan,China)

机构地区：[1]四川省肿瘤医院·研究所,四川省癌症防治中心,电子科技大学医学院肿瘤内科,成都610041

出　　处：《肿瘤预防与治疗》2022年第9期875-881,共7页Journal of Cancer Control And Treatment

基　　金：国家自然科学基金(编号:82003196);四川省杰出青年科技人才(编号:2022JDJQ0059)。

摘　　要：弥漫性大B细胞淋巴瘤(diffuselargeBlymphoma,DLBCL)是最常见的淋巴瘤亚型,占成人非霍奇金淋巴瘤的30%~40%。其中大约30%~40%的DLBCL患者治疗后仍会复发或无法通过一线化疗获得缓解,称为复发/难治DLBCL,并且预后较差。最近多项研究表明新兴的免疫化学疗法在复发/难治DLBCL中显示出较好的抗肿瘤活性,部分患者实现了长期缓解,因此本文对复发/难治DLBCL患者免疫化学疗法的研究进展进行综述,以期待为复发/难治DLBCL患者带来更好的治疗方案。Diffuse large B-cell lymphoma(DLBCL) is the most common lymphoma, accounting for 30%-40% of adult non-Hodgkin lymphoma(NHL). About 30%-40% of DLBCL patients will relapse after treatment or fail in first-line chemotherapy. It is called relapsed or refractory DLBCL which has poor prognosis. Several recent studies have shown that immunochemotherapy shows good antitumor activity in relapsed and refractory DLBCL patients, some of which have achieved a long-term remission. Therefore, this paper reviews the research progress of immunochemotherapy in relapsed or refractory DLBCL patients, hoping to bring better treatment schemes for relapsed/refractory DLBCL patients.

关 键 词：弥漫性大B淋巴瘤 免疫治疗 预后 淋巴瘤 复发 难治 

分 类 号：R733.4[医药卫生—肿瘤]